There are no systems in place to enable compliance with the requirements of the Food Drug and Cosmetic Act Section S82(c)(A) & (B) and (d)(A) & (B).
Inspection Record
Valisure, LLC — FDA 483 Findings
Inspectors Jonah S. Ufferfilge · Robert J. MartinThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The firm's laboratory investigations are inadequate.
The firm failed to adequately validate and/or verify analytical methods used in the evaluation of pharmaceutical products in that the firm failed to document the validation/verification process acceptance criteria, and an evaluation of the validity of the method outlining its intended use.
Trading partners must have systems in place to make a notification of illegitimate product to FDA and immediate trading partners within 24 hours after making such a determination.
A record as of the US FDA document published on 2023-01-06. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.